SCHEMBL20119909

SCHEMBL20119909

Clc1nc(NCc2ccncn2)c2c(Cl)c[nH]c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.39
KCNA5 P22460 3/20 0.39
PIM1 P11309 2/20 0.39
CDK5 Q00535 2/20 0.39
CDK5R1 Q15078 2/20 0.39
JAK2 O60674 2/20 0.39
TYK2 P29597 2/20 0.39
GSK3B P49841 2/20 0.39
JAK3 P52333 2/20 0.39
BTK Q06187 2/20 0.39
AURKB Q96GD4 2/20 0.39
IRAK4 Q9NWZ3 2/20 0.39
IGF1R P08069 1/20 0.39
SRC P12931 1/20 0.39
CSNK2A2 P19784 1/20 0.39
JAK1 P23458 1/20 0.39
CCNE1 P24864 1/20 0.39
FLT4 P35916 1/20 0.39
FLT3 P36888 1/20 0.39
MAP3K8 P41279 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119892 0.89 KCNH3 (0.43) CDK2KCNA5PIM1CDK5CDK5R1
SCHEMBL20119730 0.88 PIM1 (0.38) CDK2KCNA5PIM1CDK5CDK5R1
SCHEMBL20119669 0.85 LRRK2 (0.48) CDK2KCNA5PIM1CDK5CDK5R1
SCHEMBL20119883 0.82 PDE5A (0.40) CHRM4TMIGD3HTR2CHTR2B
SCHEMBL20119640 0.79 KCNH3 (0.40) CDK2KCNA5PIM1CDK5CDK5R1
SCHEMBL20119693 0.79 KCNH3 (0.40) CDK2KCNA5PIM1CDK5CDK5R1
SCHEMBL20119422 0.76 KCNH3 (0.41) CDK2KCNA5PIM1CDK5CDK5R1
SCHEMBL17933806 0.75 PLK4 (0.41) CDK2KCNA5PIM1CDK5CDK5R1
SCHEMBL20119881 0.73 HRH4 (0.37) CDK2KCNA5PIM1CDK5CDK5R1
SCHEMBL20119739 0.73 KCNH3 (0.38) CDK2KCNA5PIM1CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885KCNA5 4283/4885PIM1 3958/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885KCNA5 4283/4885PIM1 3958/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885KCNA5 4283/4885PIM1 3958/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885KCNA5 4283/4885PIM1 3958/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885KCNA5 4283/4885PIM1 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.